Entero Therapeutics Inc. ENTO

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
—
Insufficient data

Ranked against 712 peers in Biotechnology

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ENTO ranks in Biotechnology

Entero Therapeutics Inc. ranks #670 of 713 scored companies in Biotechnology by moat score — the top 94%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
666 Checkpoint Therapeutics, Inc. CKPT 0/100 Weak
667 CARGO Therapeutics, Inc. CRGX 0/100 Weak
668 COSCIENS Biopharma Inc. CSCI 0/100 Weak
669 Elevation Oncology, Inc. ELEV 0/100 Weak
670 Entero Therapeutics Inc. ENTO 0/100 Weak
671 ESSA Pharma Inc. EPIX 0/100 Weak
672 89bio, Inc. ETNB 0/100 Weak
673 Eyenovia, Inc. EYEN 0/100 Weak
674 GENFIT S.A. GNFT 0/100 Weak

See every Biotech / Pre-Revenue company ranked by moat score →

How ENTO scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Not measurable · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Not measurable · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ENTO's moat

What is Entero Therapeutics Inc.'s moat score?

Entero Therapeutics Inc. (ENTO) scores 0 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #670 of 713 scored companies in Biotechnology, the top 94%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology.

How does Entero Therapeutics Inc. compare with other Biotechnology companies?

Entero Therapeutics Inc. ranks #670 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Elevation Oncology, Inc. (ELEV) at 0 just above it and ESSA Pharma Inc. (EPIX) at 0 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Entero Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Entero Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and ENTO scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (not measurable), Resilience (not measurable), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000